Annovis begins treatment of subjects in Alzheimer's trial [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
Clinical Trials Arena · Chinnapong/Shutterstock GlobalData Thu, February 6, 2025 at 5:21 PM GMT+1 2 min read In This Article ANVS Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the efficacy and safety of buntanetap in treating early Alzheimer's disease (AD). The treatment period in the placebo-controlled, double-blind trial is said to span 18 months. The trial will comprise two segments: a six-month evaluation focused on assessing symptomatic effects followed by a 12-month evaluation period to assess the therapy's disease-modifying effects. More than 750 subjects are expected to be enrolled across approximately 100 US sites. Conquest Research in Winter Park, Florida, as well as Advanced Memory Research Institute of New Jersey in Tom's River are the first two sites to begin recruitment. The primary outcomes of the trial include assessing cognition using the Alzheimer's Disease Assessment Scale-
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients [Yahoo! Finance]Yahoo! Finance
- Annovis Announces Open-Label Extension Study for Parkinson's Disease PatientsGlobeNewswire
- Annovis to Host Corporate Update Webinar on January 28, 2026GlobeNewswire
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study GroupGlobeNewswire
- Annovis Announces Two Presentations at the CTAD 2025 ConferenceGlobeNewswire
ANVS
Analyst Actions
- 9/30/25 - Canaccord Genuity
ANVS
Sec Filings
- 12/8/25 - Form 4
- 11/25/25 - Form 4/A
- 11/25/25 - Form 4
- ANVS's page on the SEC website